PARP1 and cancer: This minireview describes some potential problems with telomerase inhibitors and introduces the telomeric poly(ADP-ribose) polymerases (PARP), tankyrase 1 and 2 (Figure 1), as the second potential target for telomere-directed molecular cancer therapeutics.